A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
Latest Information Update: 20 Mar 2026
At a glance
- Drugs GSK 4023393A (Primary) ; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A B C Y W-135 conjugate
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms MENACWY-MEN7B-003
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 20 Mar 2026 Planned number of patients changed from 688 to 703.
- 18 May 2025 Status changed from active, no longer recruiting to completed.
- 30 Dec 2023 This trail has been discontinued in Finland ,as per Eudra Record